Gut bacteria boost? probiotic added to chemo in breast cancer trial

NCT ID NCT06768931

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding an oral probiotic (Biolosion) to standard chemotherapy before surgery can help eliminate more cancer cells in women with early-stage triple-negative breast cancer. About 192 participants will receive either standard treatment alone or standard treatment plus the probiotic. The main goal is to see if more cancers completely disappear by the time of surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER EARLY-STAGE BREAST CANCER IMMUNOTHERAPY PROBIOTIC TRIPLE-NEGATIVE BREAST CANCER (TNBC)

Contacts and locations

Locations

Central Hospital of Guangdong Nongken
NOT_YET_RECRUITING

Zhanjiang, Guangdong, 524002, China
Dongguan People's Hospital
NOT_YET_RECRUITING

Dongguan, Guangdong, 523059, China
Gansu Cancer Hospital
NOT_YET_RECRUITING

Lanzhou, Gansu, 730050, China
Sun yat sen university cancer center
RECRUITING

Guangzhou, Guangdong, 510060, China
Zigong Fourth People's hospital
NOT_YET_RECRUITING

Zigong, Sichuan, 643000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.